{"organizations": [], "uuid": "4fbe99d605d8261fe7314d8c89dcaaa54d24e81a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-urogen-pharma-reports-q4-loss-per/brief-urogen-pharma-reports-q4-loss-per-share-of-0-74-idUSASC09SDY", "country": "US", "domain_rank": 408, "title": "BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-15T13:17:00.000+02:00", "replies_count": 0, "uuid": "4fbe99d605d8261fe7314d8c89dcaaa54d24e81a"}, "author": "", "url": "https://www.reuters.com/article/brief-urogen-pharma-reports-q4-loss-per/brief-urogen-pharma-reports-q4-loss-per-share-of-0-74-idUSASC09SDY", "ord_in_thread": 0, "title": "BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-urogen pharma", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "urogen pharma ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 15, 2018 / 11:17 AM / Updated 8 minutes ago BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74 Reuters Staff March 15 (Reuters) - Urogen Pharma Ltd: * UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS * Q4 LOSS PER SHARE $0.74 * Q4 EARNINGS PER SHARE VIEW $-0.62 — THOMSON REUTERS I/B/E/S * ‍TOP-LINE DATA FROM OLYMPUS PIVOTAL TRIAL ARE EXPECTED IN Q3 2018.​ * ‍POTENTIAL APPROVAL AND COMMERCIAL LAUNCH OF MITOGEL IN UNITED STATES IS TARGETED FOR H2 2019​ * ‍AS OF DECEMBER 31, 2017, CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALED $73.0 MILLION​ * ‍ ASSUMING POSITIVE RESULTS, PLANNED SUBMISSION OF NDA TO U.S. FDA IN Q1 2019 FOR MITOGEL​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-03-15T13:17:00.000+02:00", "crawled": "2018-03-15T13:38:52.002+02:00", "highlightTitle": ""}